Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study

OBJECTIVE: Secukinumab provided sustained efficacy, low radiographic progression and consistent safety over 52 weeks in patients with psoriatic arthritis (PsA) in the FUTURE 5 study. Here, we report 2-year (end-of-study) results from this study. METHODS: Adults with active PsA were randomised 2:2:2:...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, Landewé, Robert, Rahman, Proton, Tahir, Hasan, Singhal, Atul, Boettcher, Elke, Navarra, Sandra, Readie, Aimee, Mpofu, Shephard, Delicha, Eumorphia Maria, Pricop, Luminita, van der Heijde, Desirée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327842/
https://www.ncbi.nlm.nih.gov/pubmed/34330846
http://dx.doi.org/10.1136/rmdopen-2021-001600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327842/
https://www.ncbi.nlm.nih.gov/pubmed/34330846
http://dx.doi.org/10.1136/rmdopen-2021-001600

Ejemplares similares